John Maraganore

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

John Maraganore

John Maraganore

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Overview
Career Highlights

Alnylam Pharmaceuticals, Inc.

RelSci Relationships

4778

Number of Boards

16

Birthday

1963

Age

58

Contact Data
Trying to get in touch with John Maraganore? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals John Maraganore likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Executive Officer, Director at Adolor Corp.

Relationship likelihood: Strong

Co-Founder at Third Rock Ventures LLC

Relationship likelihood: Strong

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Former Venture Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

Executive Vice President, Chief Legal Officer & Secretary at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

General Partner at Google Ventures

Relationship likelihood: Strong

Vice President of Research & RLD at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

President-Research & Development at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Chairman at CytomX Therapeutics, Inc.

Relationship likelihood: Strong

Paths to John Maraganore
Potential Connections via
Relationship Science
You
John Maraganore
Chief Executive Officer at Alnylam Pharmaceuticals, Inc.
Education
MS in Biochemistry & Molecular Biology

UCE’s Office of Investments is responsible for managing the University's investment assets, which includes overseeing the endowment to ensure that it benefits both current and future generations of the University of Chicago. They oversee the broad investment strategy and provide input to the development of the strategic and tactical investment policies of the University & UCMC endowments, pension plans and self-insurance trust assets. Their strategy combines qualitative and quantitative analysis, seeking to achieve superior investment performance on a risk-adjusted basis.

Memberships
Member
Current

CEO Action For Diversity & Inclusion is the CEO-driven business commitment to advance diversity and inclusion within the workplace. The company is headquartered in Chicago, IL.

Career History
General Manager
Prior
General Manager of Millennium BioTherapeutics
2000 - 2002

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Director-Market & Business Development
Prior

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

Boards & Committees
Lead Independent Director
2011 - Current

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Board Advisor
2009 - Current

Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA.

Director & Chief Executive Officer
Current

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Member, Board of Directors
Current

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Member, Research Advisory Board
Current

Beth Israel Deaconess Hospital operates as a teaching hospital of Harvard Medical School. It offers care for cancer, cardiovascular, diabetes and spine. The company is headquartered in Needham, MA.

Member, Immunology Advisory Council
Tenure Unconfirmed

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.The school was founded by John Warren on September 19, 1782, with Benjamin Waterhouse, and Aaron Dexter.

Investments
Details Hidden

Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by John Maraganore. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of John Maraganore's profile does not indicate a business or promotional relationship of any kind between RelSci and John Maraganore.